GLP-1 Market Monitor
Active companies
Other 🇬🇧, United Kingdom
Poolbeg Pharma develops investigational treatments and is funding an oral GLP-1 proof-of-concept trial alongside its POLB 001 TOPICAL trial. Its activity in this market includes raising capital to support clinical development. This profile follows its financing, partnerships and progress across the programs covered by our monitors.
Market cap not yet added.
Last 12 months
Last 12 months
Active companies
Investors will provide Poolbeg with £3.5 million in exchange for new shares. Poolbeg says the money will help fund trials of a GLP-1 obesity treatment taken by mouth and a separate cancer-support medicine.